Full Text View
Tabular View
Study Results
Related Studies
Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions
This study has been completed.
Study NCT00835263   Information provided by Teva Pharmaceuticals USA

First Received on January 30, 2009.   Last Updated on September 1, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Healthy
Interventions listed in this trial
Lamotrigine
Lamictal®
More general drug interventions related to this trial
Anticonvulsants
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Teva Pharmaceuticals USA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services